Back

Impact of worsening heart failure events and renal impairment on vericiguat drug use patterns in real-world care

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Medical therapy in the context of acute heart failure Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Fabian Kerwagen

University Hospital Wuerzburg, Wuerzburg (Germany)

5 More presentations in this session

Presentation thumbnail
Changes in medicines use before and after hospitalisation for heart failure: Australian nationwide cohort study
Doctor H. Raaket (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Relationship between left ventricular reverse remodeling and guideline-directed medical therapy intensity in de novo heart failure with reduced ejection fraction patients: insight from TRANS-HF trial
Doctor C. Lee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Discharge medical treatment implementation in patients admitted for AHF: preliminary data from the BRING-UP3 HF study
Doctor M. Gori (Bergamo, IT)
Abstract Slides Video
Presentation thumbnail
Initiation and titration of prognostic drug therapy during hospitalization for acute decompensation of heart failure with reduced ejection fraction
Mrs S. Valdivielso (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Pre-discharge versus post-discharge initiation of quadruple medical therapy in acute heart failure with reduced ejection fraction: Insights from the MCR-HF Registry
Mr N. Phan (Ho Chi Minh, VN)
Abstract Slides Video

Access the full session

Session thumbnail
Medical therapy in the context of acute heart failure

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Risk of all-cause mortality and heart failure hospitalizations in patients treated with vericiguat in real world settings
thumbnail
Congress Presentation
Age- and sex-specific characteristics and real-world use patterns of patients treated with vericiguat in Germany
thumbnail
Congress Presentation
Incidence of cardiovascular events following vericiguat initiation in patients with heart failure with or without a recent worsening heart failure event: a hospital-based real-world cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources